Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help.Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L

Autor: Lederman, S, Yellin, Mj, Inghirami, Giorgio, Lee, Jj, Knowles, Dm, Chess, L.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______970::1c10bbd44ba4af338343b6035fd49059
http://hdl.handle.net/2318/121221

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Autor: Weller, M, Butowski, N, Tran, DD, Recht, LD, Lim, M, Hirte, H, Ashby, L, Mechtler, L, Goldlust, SA, Iwamoto, F, Drappatz, J, O'Rourke, DM, Wong, M, Hamilton, MG, Finocchiaro, G, Perry, J, Wick, W, Green, J, He, Y, Turner, CD, Yellin, MJ, Keler, T, Davis, TA, Stupp, R, Sampson, JH, Campian, J, Recht, L, Goldlust, S, Becker, K, Barnett, G, Nicholas, G, Desjardins, A, Benkers, T, Wagle, N, Groves, M, Kesari, S, Horvath, Z, Merrell, R, Curry, R, O'Rourke, J, Schuster, D, Mrugala, M, Jensen, R, Trusheim, J, Lesser, G, Belanger, K, Sloan, A, Purow, B, Fink, K, Raizer, J, Schulder, M, Nair, S, Peak, S, Brandes, A, Mohile, N, Landolfi, J, Olson, J, Jennens, R, DeSouza, P, Robinson, B, Crittenden, M, Shih, K, Flowers, A, Ong, S, Connelly, J, Hadjipanayis, C, Giglio, P, Mott, F, Mathieu, D, Lessard, N, Sepulveda, SJ, Lövey, J, Wheeler, H, Inglis, PL, Hardie, C, Bota, D, Lesniak, M, Portnow, J, Frankel, B, Junck, L, Thompson, R, Berk, L, McGhie, J, Macdonald, D, Saran, F, Soffietti, R, Blumenthal, D, André de, SBCM, Nowak, A

Publikováno v: Weller, M; Butowski, N; Tran, DD; Recht, LD; Lim, M; Hirte, H; et al.(2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. The Lancet Oncology, 18(10), 1373-1385. doi: 10.1016/S1470-2045(17)30517-X. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/2sg9m5wp

© 2017 Elsevier Ltd Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::6bdef254233643727bdc6e1e7e8761af
http://www.escholarship.org/uc/item/2sg9m5wp

Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.

Autor: Bhardwaj N; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. nina.bhardwaj@mssm.edu., Friedlander PA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Pavlick AC; NYU Perlmutter Cancer Center, New York, NY, USA., Ernstoff MS; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Gastman BR; Cleveland Clinic, Cleveland, OH, USA., Hanks BA; Duke University Medical Center, Durham, NC, USA., Curti BD; Providence Portland Medical Center, Portland, OR, USA., Albertini MR; University of Wisconsin, Madison, WI, USA., Luke JJ; University of Chicago Comprehensive Cancer Center, Chicago, IL, USA., Blazquez AB; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Balan S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Bedognetti D; Sidra Medicine, Doha, Qatar., Beechem JM; NanoString Technologies, Seattle, WA, USA., Crocker AS; Celldex Therapeutics, Hampton, NJ, USA., D'Amico L; Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Danaher P; NanoString Technologies, Seattle, WA, USA., Davis TA; Genocea Biosciences, Cambridge, MA, USA., Hawthorne T; Celldex Therapeutics, Hampton, NJ, USA., Hess BW; Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Keler T; Celldex Therapeutics, Hampton, NJ, USA., Lundgren L; Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Morishima C; University of Washington, Seattle, WA, USA., Ramchurren N; Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Rinchai D; Sidra Medicine, Doha, Qatar., Salazar AM; Oncovir, Inc., Washington, DC, USA., Salim BA; Axio Research, Seattle, WA, USA., Sharon E; National Institutes of Health, Bethesda, MD, USA., Vitale LA; Celldex Therapeutics, Hampton, NJ, USA., Wang E; Sidra Medicine, Doha, Qatar., Warren S; NanoString Technologies, Seattle, WA, USA., Yellin MJ; Celldex Therapeutics, Hampton, NJ, USA., Disis ML; University of Washington, Seattle, WA, USA., Cheever MA; Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Fling SP; Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. sfling@fredhutch.org.

Publikováno v: Nature cancer [Nat Cancer] 2020 Dec; Vol. 1 (12), pp. 1204-1217. Date of Electronic Publication: 2020 Nov 16.

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.

Autor: Reardon DA; Dana-Farber Cancer Institute, Boston, Massachusetts., Desjardins A; Duke University Medical Center, Durham, North Carolina., Vredenburgh JJ; Saint Francis Hospital and Medical Center, Hartford, Connecticut., O'Rourke DM; University of Pennsylvania, Philadelphia, Pennsylvania., Tran DD; Washington University, St. Louis, Missouri., Fink KL; Baylor Research Institute, Dallas, Texas., Nabors LB; University of Alabama at Birmingham, Birmingham, Alabama., Li G; Stanford University School of Medicine, Stanford, California., Bota DA; UC Irvine Medical Center, Irvine, California., Lukas RV; University of Chicago, Chicago, Illinois., Ashby LS; Barrow Neurological Institute, Phoenix, Arizona., Duic JP; Department of Neurosciences, Winthrop University Hospital, Mineola, New York., Mrugala MM; University of Washington School of Medicine, Seattle, Washington., Cruickshank S; Scott Cruickshank and Associates, Santa Barbara, California., Vitale L; Celldex Therapeutics, Inc., Hampton, New Jersey., He Y; Celldex Therapeutics, Inc., Hampton, New Jersey., Green JA; Celldex Therapeutics, Inc., Hampton, New Jersey., Yellin MJ; Celldex Therapeutics, Inc., Hampton, New Jersey., Turner CD; Celldex Therapeutics, Inc., Hampton, New Jersey., Keler T; Celldex Therapeutics, Inc., Hampton, New Jersey., Davis TA; Celldex Therapeutics, Inc., Hampton, New Jersey., Sampson JH

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Apr 01; Vol. 26 (7), pp. 1586-1594. Date of Electronic Publication: 2020 Feb 07.

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.

Autor: Weller M; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland. Electronic address: michael.weller@usz.ch., Butowski N; Department of Neurological Surgery, University of California, San Francisco, CA, USA., Tran DD; Washington University, St Louis, MO, USA., Recht LD; Stanford University Medical Center, Palo Alto, CA, USA., Lim M; The Johns Hopkins Hospital, Baltimore, MD, USA., Hirte H; Juravinski Cancer Centre, Hamilton, ON, Canada., Ashby L; Barrow Neurological Institute, Phoenix, AZ, USA., Mechtler L; DENT Neurologic Institute, Buffalo, NY, USA., Goldlust SA; John Theurer Cancer Center, Hackensack, NJ, USA., Iwamoto F; Columbia University Medical Center, New York, NY, USA., Drappatz J; University of Pittsburgh Medical Center, Pittsburgh, PA, USA., O'Rourke DM; Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Wong M; Westmead Hospital, Westmead, NSW, Australia., Hamilton MG; University of Calgary, Department of Clinical Neurosciences, Division of Neurosurgery, Foothills Hospital, Calgary, AB, Canada., Finocchiaro G; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy., Perry J; Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Wick W; The University of Heidelberg and German Cancer Research Center, Heidelberg, Germany., Green J; Celldex Therapeutics, Inc, Hampton, NJ, USA., He Y; Celldex Therapeutics, Inc, Hampton, NJ, USA., Turner CD; Celldex Therapeutics, Inc, Hampton, NJ, USA., Yellin MJ; Celldex Therapeutics, Inc, Hampton, NJ, USA., Keler T; Celldex Therapeutics, Inc, Hampton, NJ, USA., Davis TA; Celldex Therapeutics, Inc, Hampton, NJ, USA., Stupp R; Department of Oncology, University Hospital and University of Zurich, Zurich, Switzerland., Sampson JH; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2017 Dec; Vol. 18 (12), pp. e709-e710.